Avid Bioservices Inc (CDMO)

[biopharm]

Epiontis scooped up by Precision for Medicine for PS Targeting biomarkers related reasons.....

Now, pay close attention to the words of David Parker at Precision For Medicine as he states "All of those are informatics technologies, that are enabling measurements and correlations to be drawn that couldn’t be drawn previously. "

.....that couldn't be drawn previously......hmmmm, as both, PFM and Epiontis were working with Biomarker data with Peregrine ....so what couldn't be drawn previously, I say.....is becoming obvious was related to Biomarkers etc discovered while ongoing colorations with Peregrine Pharmaceuticals now called Avid Bioservices. Remember also...Bird/Bird goes on record as the reason why the purchase of Epiontis was made by PFM and possibly for legal reasons.

Genetic Engineering & Biotechnology

Sept/Oct 2017
....
....

Clinical OMICs: What do you see as the big issues in the complementary and companion diagnostic area in the next few years?

David Parker, Ph.D.
David Parker, Ph.D., SVP, Diagnostics Solutions, Precision for Medicine: There are a number of things. It will be technologies that, when applied to biological specimens, allow multiple markers to be assayed simultaneously. I’m thinking specifically about mass spec. It’s been around a long time. It is not typically applied to biomarker analysis, but increasingly it is, in part because it allows multiple analytes to be assayed in the same sample and the same assay. So enabling technologies like that that allow multiple biomarkers to be assayed simultaneously is one.

The other is informatics in a couple of dimensions. It is applications of digital technologies that allow correlation and measurements to be made that never could be previously. Another could be identifying biomarker signatures out of multiple streams of omic data: proteomic, genomic, and the like. They are disparate streams, but can you find patterns that are in and of themselves a biomarker. And the third is the Foundation [Medicine] deep curation. Can we correlate every single piece of scientific knowledge known about this mutation in a way that might reveal some clinical utility?

All of those are informatics technologies, that are enabling measurements and correlations to be drawn that couldn’t be drawn previously.

https://www.genengnews.com/gen-exclusives/of-biomarkers-and-cdxes/77900989